<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739177</url>
  </required_header>
  <id_info>
    <org_study_id>002</org_study_id>
    <nct_id>NCT03739177</nct_id>
  </id_info>
  <brief_title>Onco4D(TM) Biodynamic Chemotherapy Selection for Bladder Cancer Patients</brief_title>
  <official_title>Feasibility Study of Motility Contrast Tomography for Predicting Therapeutic Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Animated Dynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Animated Dynamics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Millions of cancer patients every year receive chemotherapy with only a 20-60% probability of&#xD;
      pathological response, while most experience adverse side effects that lower quality of life&#xD;
      without prolonging it. Reliable identification of ineffective therapies can eliminate&#xD;
      needless human suffering while increasing overall probability of positive response to&#xD;
      treatment. Chemotherapy resistance profiling entails testing whether a patient exhibits&#xD;
      strong resistance to a therapy prior to its final selection by the oncologist. However, there&#xD;
      are no effective methods for quickly assessing patient chemotherapy resistance. Patient&#xD;
      Derived Xenograft (PDX) models have replaced older Chemotherapy Sensitivity and Resistance&#xD;
      Assays (CSRAs) to some degree, but both technologies suffer from long testing times, high&#xD;
      cost, and/or low accuracy.&#xD;
&#xD;
      Motility Contrast Tomography (MCT) has recently emerged as a technology that measures the&#xD;
      biodynamic response of intact tumor biopsies to applied therapeutics by using Doppler&#xD;
      detection of infrared light scattered from intracellular motions inside living tissue.&#xD;
      Several small scale animal, xenograft, and human studies have shown this phenotypic profiling&#xD;
      technique to be highly accurate in prediction of response and resistance to chemotherapy.&#xD;
      This project will be the first human trial of biodynamic phenotyping to predict chemotherapy&#xD;
      response among bladder cancer patients. Specifically, the study cohort will include patients&#xD;
      selected for neoadjuvant chemotherapy treatment, because this setting offers the opportunity&#xD;
      for near-term outcome measurement at the time of post-chemo surgery. Pre-therapy fresh tumor&#xD;
      specimens will be imaged using MCT, and the resulting bio-dynamic signatures will be compared&#xD;
      to confirmed pathological response at the time of surgery. Observation of a high predictive&#xD;
      value will provide the basis for expanded clinical trials and prompt commercialization of a&#xD;
      biodynamic chemotherapy selection assay for bladder and other cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY RATIONALE: The demonstrated ability of MCT to accurately assess tumor xenografts may&#xD;
      establish it as a reliable technique for patient tumor stratification based on predicted&#xD;
      response to therapy, which could enable a treatment selection based on the personal needs of&#xD;
      an individual patient. This study is designed to assess MCT as an assay for predicting&#xD;
      chemosensitivity to treatment with chemotherapy agents routinely used in the neoadjuvant and&#xD;
      adjuvant treatment of bladder cancer. If positive, the results of this study will provide the&#xD;
      basis for expanded clinical trials and use of MCT in therapy selection.&#xD;
&#xD;
      BACKGROUND: Live cell imaging has become the standard for high-content analysis and drug&#xD;
      discovery applications. The most common assays on live cells include viability, proliferation&#xD;
      and cytotoxicity assays as cellular physiology and function are measured responding to&#xD;
      applied perturbations of xenobiotics. Cellular and tissue viability assays are typically&#xD;
      measured using exogenous vital dyes as biomarkers of membrane integrity or cellular metabolic&#xD;
      activity. However, dyes are invasive, potentially toxic, and often require fixing of the&#xD;
      tissue or permeabilization of the membranes. Furthermore, the common format of high content&#xD;
      analysis and flow cytometry requires isolated cells, or cells distributed on flat hard&#xD;
      surfaces. Isolated cells lack many of the biologically-relevant intercellular connections and&#xD;
      communications that are hallmarks of healthy tissue, and flattened cells on plates have&#xD;
      pathological shapes and anisotropic cellular adhesions.&#xD;
&#xD;
      Discovery of technology that can predict response to cancer therapy is an urgent priority.&#xD;
      While many technologies exist to evaluate early response to drugs ex vivo, the need to&#xD;
      perform viability, cytotoxicity and proliferation assays in three-dimensional tissue or&#xD;
      culture has become increasingly urgent, as drug response in 2D is often not the same as drug&#xD;
      response in biologically-relevant three dimensional culture. This is in part because genomic&#xD;
      profiles are not preserved in monolayer cultures. There have been several studies that have&#xD;
      tracked the expression of genes associated with cell survival, proliferation, differentiation&#xD;
      and resistance to therapy that are expressed differently in 2D cultures relative to&#xD;
      three-dimensional culture. For example, cell lines of epithelial ovarian cancer,&#xD;
      hepatocellular carcinoma, or colon cancer display expression profiles more like those from&#xD;
      tumor tissues when measured in three-dimensional culture, but not when grown in 2D. In&#xD;
      addition, the three-dimensional environment of 3D culture presents different pharmacokinetics&#xD;
      than 2D monolayer culture and produce differences in cancer drug sensitivities. Finally, most&#xD;
      current technologies rely on destructive end-point assessment, preventing meaningful&#xD;
      longitudinal observation of therapy response over time.&#xD;
&#xD;
      One of the main challenges to migrating drug-response assays to the third and fourth&#xD;
      dimensions has been to find a means to extract vital information from deep (up to a&#xD;
      millimeter) inside living tissue. Tissue is translucent and light can propagate diffusively&#xD;
      many centimeters. Furthermore, the dynamic motions of living cells cause dynamic light&#xD;
      scattering that produces phase fluctuations on the scattered light fields that can be&#xD;
      measured as dynamic speckle in diffusely reflected light from tissue. This is the basis of&#xD;
      diffusing wave spectroscopy (DWS) and diffusion correlation spectroscopy (DCS), but these&#xD;
      techniques lack depth resolution. A powerful tool in the characterization of light&#xD;
      propagation in tissues is the use of interferometry. Interferometric detection is the&#xD;
      underlying process in optical coherence tomography (OCT), which is a point-scanning technique&#xD;
      that suppresses speckle, although speckle decorrelation in OCT data can provide similar&#xD;
      information as provided by DCS. This has been used to measure intracellular rheology and to&#xD;
      find dynamic signatures of apoptosis. Transport also can be detected at cellular resolution&#xD;
      using phase contrast microscopy, but this approach cannot be used in thick tissues.&#xD;
&#xD;
      Dr. Nolte and colleagues have developed volumetrically-resolved tissue dynamic imaging that&#xD;
      uses the advantages of depth selectivity from low-coherence interferometry, combined with&#xD;
      high speckle contrast in broad-illumination digital holography. The technique is called&#xD;
      Motility Contrast Tomography (MCT) and uses low-coherence digital holography to penetrate up&#xD;
      to 1 millimeter into living tissue to measure speckle dynamics from light scattering from&#xD;
      dynamic motion in living cells. It was previously applied as a cytotoxicity assay to study&#xD;
      the efficacy of anti-mitotic drugs. In essence, the technology works by profiling the&#xD;
      'movement' of cellular organelles. Specific changes in organelle motion are detectable very&#xD;
      early in cells undergoing response to chemotherapy treatment, and may be usable as an early&#xD;
      predictor of chemotherapy response.&#xD;
&#xD;
      MCT is based on optical coherence imaging (OCI). OCI is a full-field short-coherence&#xD;
      holography that collects backscattered speckle. With the help of coherence gating, OCI can&#xD;
      optically section tissue up to 1 mm deep. MCT specifically uses intracellular motion as the&#xD;
      endogenous contrast to characterize submicron subcellular motion inside three-dimensional&#xD;
      living tissue.&#xD;
&#xD;
      EX VIVO CANCER CHEMOSENSITIVITY ANALYSIS MCT was previously applied to study the efficacy of&#xD;
      anti-mitotic drugs using multicellular tumor spheroids. When applying MCT to tumor&#xD;
      xenografts, it is also capable of showing a significantly different response between two cell&#xD;
      lines under cisplatin. After applying the drug, the normalized standard deviation (NSD) value&#xD;
      of the platinum-sensitive cell line (A2780) drops from 0.7 to 0.1 in 8 hours. In contrast,&#xD;
      the NSD value of the platinum-resistant cell line (A2780-CP70) remains nearly constant (0.81&#xD;
      to 0.80) 9 hours after applying drug. The NSD value of normal mouse tissue attached to the&#xD;
      tumor xenograft decreases only a little (0.6 to 0.52) compared with A2780.&#xD;
&#xD;
      In a further study in a veterinary clinical setting, MCT has been used to predict patient&#xD;
      outcome for canine non-Hodgkin's lymphoma. Canine non-Hodgkin's lymphomas are initially&#xD;
      characterized by tumoral infiltration of peripheral lymph nodes. Canine non-Hodgkin's&#xD;
      lymphomas are diverse in their clinical aggressiveness and response to chemotherapy. The only&#xD;
      current biomarker for chemoresponsiveness is tumor cell immunophenotype (i.e. T-cell vs.&#xD;
      B-cell origin), but chemoresponsiveness varies tremendously within immunophenotype, which&#xD;
      reduces the clinical utility of this biomarker. In our study, we used MCT to measure the&#xD;
      heterogeneous response of canine lymphoma biopsies to the standard-of-care doxorubicin. The&#xD;
      biodynamic signatures of doxorubicin responsivity ex vivo were correlated with canine patient&#xD;
      outcome. These studies have demonstrated, for the first time, the utility of label-free&#xD;
      intracellular biodynamic markers to predict therapeutic efficacy for cancer treatment in&#xD;
      dogs.&#xD;
&#xD;
      SPECIFIC AIMS The primary study objective is to examine the feasibility of using MCT as a&#xD;
      chemosensitivity assay among bladder cancer patients receiving neoadjuvant chemotherapy by&#xD;
      comparing MCT patterns consistent with chemotherapy response or resistance ex-vivo to&#xD;
      confirmed response or resistance to chemotherapy as measured by Response Evaluation Criteria&#xD;
      in Solid Tumors (RECIST) v1.1 criteria.&#xD;
&#xD;
      PRIMARY ENDPOINT: Objective pathological response measured at the time of surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective pathological response measured at the time of cystectomy.</measure>
    <time_frame>Cystectomy is generally expected to occur 12-16 weeks after biopsy is obtained from a TURBT procedure.</time_frame>
    <description>The study will be considered successful, if a majority of specimens yield interpretable MCT results, and if MCT signatures are identified which demonstrate a high statistical correlation to confirmed patient response.</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Onco4D Biodynamic Chemotherapy Selection Assay</intervention_name>
    <description>The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of all races and ethnic groups are eligible for this study. Patients will be&#xD;
        recruited from participating sites after interpretation of imaging or other factors&#xD;
        indicative of bladder cancer, but prior to performance of a TURBT procedure per routine&#xD;
        care guidelines.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA: To be eligible for the study, participants must meet the following&#xD;
        criteria:&#xD;
&#xD;
          1. Ability to understand and willingness to sign an informed consent and authorization&#xD;
             for release of tissue not required for pathologic diagnosis to be used for research&#xD;
             purposes&#xD;
&#xD;
          2. â‰¥ 18 years old at time of consent&#xD;
&#xD;
          3. Patients undergoing a TURBT procedure due to diagnose muscle invasive bladder cancer&#xD;
&#xD;
        EXCLUSION CRITERIA: To be eligible for the study, participants must not be or have any of&#xD;
        the following:&#xD;
&#xD;
          1. Women who are pregnant or breastfeeding&#xD;
&#xD;
          2. Known tumor genetics or other factors, which in the treating physician's professional&#xD;
             judgement, make the patient an unlikely candidate to receive chemotherapy (either&#xD;
             neoadjuvantly or adjuvantly)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Travis A Morgan, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Animated Dynamics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Travis A Morgan, MBA</last_name>
    <phone>800-963-3313</phone>
    <phone_ext>702</phone_ext>
    <email>tmorgan@anidyn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Animated Dynamics, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Travis A Morgan</last_name>
      <phone>800-963-3313</phone>
      <phone_ext>702</phone_ext>
      <email>tmorgan@anidyn.com</email>
    </contact>
    <investigator>
      <last_name>Ran An, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant Chemotherapy, Muscle Invasive Bladder Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03739177/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

